Milestones

1. Consolidation and reinforcement of the strategic line on first psychotic episodes, in effect since the group's inception, through the development of the CAM's AGES-CM3 (S2022/BMD-7216) and ISCIII's SchizOMICS (ICI21/00089) and FARMAPRED-PEP (PMP21/00085) projects, with publications focused on biological, clinical, and functional predictors of the evolution and relapse.
2. Advances in the field of epigenetics and genetics/pharmacogenetics of mental disorders, with publications on methylation profiles, polygenic risk, and biomarkers, which contribute to a better understanding of the biological mechanisms involved in clinical evolution.
3. High-impact publication on the study of epigenetic factors associated with the risk of relapse in first psychotic episodes. Segura AG, Prohens L, Julià L, Amoretti S, RIbero M, Pino L, Cano G, Mane A, Rodriguez R, Roldan A, Sarró S, Ibañez Á, Usall J, Lobo A, Garcia C, Cuesta MJ, Parellada M, González A, Berrocoso E, Bernardo M, Mas S, Rodríguez N, 2EPS G, Perez A, Salmeron S, González J, Gurriarán X, Farré A, Pousa E, Zorrilla I, Mar L, Trabsa A, Martinez L, Sánchez Á, Jiménez E, Pomarol E, Salvador R, Butjosa A, Elena RA, Moreno L, Torres A, Saiz J, León L, Rivero O, González L, De C. Methylation profile scores of environmental exposures and risk of relapse after a fi rst episode of schizophrenia. Eur. Neuropsychopharmacol. 2025;94: 4 - 15. DOI:10.1016/j.euroneuro.2025.02.003.
4. The strategic focus on affective disorders is maintained, highlighting an article of particular clinical relevance on The DEPRE'5 study, a pragmatic, multicenter, randomized trial: Pérez V, Puigdemont D, de Diego J, Elices M, Leal I, Cabello M, Rodriguez R, Álvarez MÁ, García L, Aguilar García EJ, Escartí MJ, Montejo AL, Montes JM, Usall J, Gallego A, Lujan E, López R, González A, Ortiz A, Blanch J, Urretavizcaya M, Colom F, García J, Ayuso JL. The DEPRE'5 study: pragmatic, multicentre, five-arm, parallel-group randomised controlled trial with blinded assessment to compare treatment strategies in major depression after a failed selective serotonin reuptake inhibitor treatment. Br. J. Psychiatry. 2025;227(5): 748 - 755. DOI:10.1192/bjp.2025.13.
5. Fraile O, García C, Álvarez MÁ, Casanova C, Fernández D, Presa M, Lahera G, Lopez L, Díaz R, Saz JV, Álvarez M, Sáez MA, Ortega MA. Grasping Post-Traumatic Stress Disorder (PTSD) from the Perspective of Psychoneuroimmunoendocrinology (PNIE): Etiopathogenic Mechanisms and Relevance for the Integrative Management. Biol. Psychiatry. 2025;98(10): 733 - 745. DOI:10.1016/j.biopsych.2025.01.014. Focused on biological etiopathogenic mechanisms and their relevance to an integrative approach to stress-related disorders.